Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8.

ABSTRACT: Using Sorafenib as a starting point, a series of potent and selective inhibitors of CDK8 was developed. When cocrystallized with CDK8 and cyclin C, these compounds exhibit a Type-II (DMG-out) binding mode.

SUBMITTER: Bergeron P 

PROVIDER: S-EPMC4904263 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature